Facilitating Clinical Implementation of Pharmacogenomics

Mrazek and Lerman examine the implementation of pharmacogenomic tests in clinical practice. The decision to use testing to increase the probability of a good response must be weighed against other issues, such as the efficacy and cost of alternative treatment options. Because the cost of testing is...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2011-07, Vol.306 (3), p.304-305
Main Authors: Mrazek, David A, Lerman, Caryn
Format: Article
Language:English
Subjects:
Clinical medicine
Costs
Diffusion of Innovation
Drug Costs
Drug-Related Side Effects and Adverse Reactions - genetics
Electronic Health Records
Evidence-Based Medicine
Genetic testing
Genetic Testing - economics
Genetic Testing - ethics
Genomics
Guidelines as Topic
Health Policy
Humans
Pharmacogenetics - trends
Pharmacology
Randomized Controlled Trials as Topic
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mrazek and Lerman examine the implementation of pharmacogenomic tests in clinical practice. The decision to use testing to increase the probability of a good response must be weighed against other issues, such as the efficacy and cost of alternative treatment options. Because the cost of testing is decreasing, cost is less likely to pose a barrier. At the center of a debate on the clinical implementation of pharmacogenomics is the threshold of evidence required for use in practice. Consistent with the Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network, the evidence threshold for implementation can be met by the existence of a strong biological rationale for a gene-drug combination, reproducible evidence linking genetic variation to drug response, and noninferiority compared with current prescribing practice.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2011.1010